Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma

Purpose To investigate the ability of systemically delivered BCNU to enhance the activity of either systemically delivered irinotecan (CPT-11) or locally delivered camptothecin from a biodegradable polymer for treatment of an intracranial 9L gliosarcoma.